Autopsy report · NCT00762359

A Safety and Efficacy Study of Lansoprazole in Preventing Aspirin-Induced Gastric and Duodenal Ulcers

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“AG-1749 superior to Gefarnate in ulcer prevention”

The sponsor’s own words in the registry.

Life of this trial

Registered 1 year 4 months after it had already started.
Ran for about 1 year 6 months before it stopped.
461 participants enrolled.
Results were posted on the registry 2 years 6 months after it ended.

Vital statistics

Status: Terminated
Phase: Phase 3
Sponsor: Takeda
Sponsor type: Industry
Conditions: Stomach Ulcer; Duodenal Ulcer
Interventions: Lansoprazole; Gefarnate
Participants: 461
Sites: 65
Countries: Japan

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.